Antibiotic lock therapy for the treatment of peripherally inserted central venous catheter-related bloodstream infection in patients with hematological malignancies: a single center retrospective study.

IF 2.4 3区 医学 Q2 HEMATOLOGY Annals of Hematology Pub Date : 2025-03-01 Epub Date: 2025-02-25 DOI:10.1007/s00277-025-06263-8
Qin Zhang, Yujia Huo, Chengfei Li, Qinggang Sun, Xi Xi, Rui Sun, Qingju Sun, Meijuan Jiang, Guang Li
{"title":"Antibiotic lock therapy for the treatment of peripherally inserted central venous catheter-related bloodstream infection in patients with hematological malignancies: a single center retrospective study.","authors":"Qin Zhang, Yujia Huo, Chengfei Li, Qinggang Sun, Xi Xi, Rui Sun, Qingju Sun, Meijuan Jiang, Guang Li","doi":"10.1007/s00277-025-06263-8","DOIUrl":null,"url":null,"abstract":"<p><p>Catheter-related bloodstream infections represent one of the most prevalent complications in patients with peripherally inserted central venous catheters (PICCs). The application of antibiotic lock therapy (ALT), particularly in patients with hematological malignancies, has not been well documented. We aim to share our experience on ALT for these patients and to evaluate its effectiveness and safety. All cases of patients with hematological malignancies who had PICC from January 2018 to October 2024 were retrospectively reviewed. Microbiologic data of PICC-related bloodstream infections (PRBSIs) were collected. A comparison was made between patients managed with ALT and those without it. Factors affecting PICC removal were also explored. A total of 45 patients experienced 67 episodes of PRBSIs, yielding an incidence rate of 2.98 per 1,000 PICC days. The median time of PRBSI onset was 42 days. Predominant pathogens included Gram-negative bacilli (49.3%) and Gram-positive cocci (35.8%). The catheter salvage rate was significantly higher at 76.5% when ALT was combined with systemic antibiotic therapy (SAT), compared to 51.5% for SAT alone (p = 0.033). 3 death events (3/34) compared with 4 death events (4/33) occurred in each therapeutic regimen (p = 0.709). Elevated procalcitonin levels (> 2ng/ml) and inadequate empirical therapy were risk factors for PICC removal; conversely, ALT served as a protective factor against it. ALT in combination with systemic antibiotics is a safe and effective approach for managing PRBSIs in patients with hematological malignancies, helping to avoid unnecessary catheter removal and could be considered in clinical practice when catheter retention is desired.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"1975-1984"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031872/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06263-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Catheter-related bloodstream infections represent one of the most prevalent complications in patients with peripherally inserted central venous catheters (PICCs). The application of antibiotic lock therapy (ALT), particularly in patients with hematological malignancies, has not been well documented. We aim to share our experience on ALT for these patients and to evaluate its effectiveness and safety. All cases of patients with hematological malignancies who had PICC from January 2018 to October 2024 were retrospectively reviewed. Microbiologic data of PICC-related bloodstream infections (PRBSIs) were collected. A comparison was made between patients managed with ALT and those without it. Factors affecting PICC removal were also explored. A total of 45 patients experienced 67 episodes of PRBSIs, yielding an incidence rate of 2.98 per 1,000 PICC days. The median time of PRBSI onset was 42 days. Predominant pathogens included Gram-negative bacilli (49.3%) and Gram-positive cocci (35.8%). The catheter salvage rate was significantly higher at 76.5% when ALT was combined with systemic antibiotic therapy (SAT), compared to 51.5% for SAT alone (p = 0.033). 3 death events (3/34) compared with 4 death events (4/33) occurred in each therapeutic regimen (p = 0.709). Elevated procalcitonin levels (> 2ng/ml) and inadequate empirical therapy were risk factors for PICC removal; conversely, ALT served as a protective factor against it. ALT in combination with systemic antibiotics is a safe and effective approach for managing PRBSIs in patients with hematological malignancies, helping to avoid unnecessary catheter removal and could be considered in clinical practice when catheter retention is desired.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗生素锁定治疗血液系统恶性肿瘤患者外周插入中心静脉导管相关血流感染:单中心回顾性研究
导管相关性血流感染是外周置入中心静脉导管(PICCs)患者最常见的并发症之一。抗生素锁定疗法(ALT)的应用,特别是在血液系统恶性肿瘤患者中的应用,尚未得到很好的记录。我们的目标是分享我们对这些患者的ALT治疗经验,并评估其有效性和安全性。回顾性分析2018年1月至2024年10月所有血液学恶性肿瘤PICC患者。收集picc相关血流感染(prbsi)的微生物学数据。对接受ALT治疗的患者和不接受ALT治疗的患者进行比较。探讨了影响PICC去除的因素。共有45名患者经历了67次prbsi发作,发生率为每1,000 PICC天2.98次。PRBSI发病的中位时间为42天。主要病原菌为革兰氏阴性杆菌(49.3%)和革兰氏阳性球菌(35.8%)。ALT联合全身抗生素治疗(SAT)的导管保留率为76.5%,明显高于单独使用SAT的51.5% (p = 0.033)。各治疗组死亡事件3例(3/34),死亡事件4例(4/33),差异有统计学意义(p = 0.709)。降钙素原水平升高(2ng/ml)和经验治疗不充分是PICC切除的危险因素;相反,ALT则起到了保护因子的作用。谷丙转氨酶联合全身抗生素治疗血液系统恶性肿瘤患者PRBSIs是一种安全有效的方法,有助于避免不必要的导管拔除,在临床实践中可以考虑留置导管。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annals of Hematology
Annals of Hematology 医学-血液学
CiteScore
5.60
自引率
2.90%
发文量
304
审稿时长
2 months
期刊介绍: Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.
期刊最新文献
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials How to talk about death? A cross-sectional survey on patients’, informal caregivers’ and health care professionals’ views in the setting of allogenic hematopoietic stem cell transplantation Correspondance: Venetoclax combined with FLAG-based chemotherapy induces rapid and deep responses in early T-cell precursor lymphoblastic leukemia/lymphoma. Report of two cases and review of the literature Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes De novo mutations in ANK1 and SPTB cause hereditary spherocytosis: three case reports and literature review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1